Mitochondrial dysfunction in Alzheimer's disease - a proteomics perspective
- PMID: 33874826
- DOI: 10.1080/14789450.2021.1918550
Mitochondrial dysfunction in Alzheimer's disease - a proteomics perspective
Abstract
Mitochondrial dysfunction is involved in Alzheimer's disease (AD) pathogenesis. Mitochondria have their own genetic material; however, most of their proteins (∼99%) are synthesized as precursors on cytosolic ribosomes, and then imported into the mitochondria. Therefore, exploring proteome changes in these organelles can yield valuable information and shed light on the molecular mechanisms underlying mitochondrial dysfunction in AD. Here, we review AD-associated mitochondrial changes including the effects of amyloid beta and tau protein accumulation on the mitochondrial proteome. We also discuss the relationship of ApoE genetic polymorphism with mitochondrial changes, and present a meta-analysis of various differentially expressed proteins in the mitochondria in AD.Area covered: Proteomics studies and their contribution to our understanding of mitochondrial dysfunction in AD pathogenesis.Expert opinion: Proteomics has proven to be an efficient tool to uncover various aspects of this complex organelle, which will broaden our understanding of mitochondrial dysfunction in AD. Evidently, mitochondrial dysfunction is an early biochemical event that might play a central role in driving AD pathogenesis.
Keywords: Alzheimer’s disease; Mitochondrial dysfunction; Proteomics.
Similar articles
-
Early Presymptomatic Changes in the Proteome of Mitochondria-Associated Membrane in the APP/PS1 Mouse Model of Alzheimer's Disease.Mol Neurobiol. 2018 Oct;55(10):7839-7857. doi: 10.1007/s12035-018-0955-6. Epub 2018 Feb 22. Mol Neurobiol. 2018. PMID: 29468564
-
Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery.Mol Neurodegener. 2021 Aug 12;16(1):55. doi: 10.1186/s13024-021-00474-z. Mol Neurodegener. 2021. PMID: 34384464 Free PMC article. Review.
-
Proteomic Profiles of the Early Mitochondrial Changes in APP/PS1 and ApoE4 Transgenic Mice Models of Alzheimer's Disease.J Proteome Res. 2019 Jun 7;18(6):2632-2642. doi: 10.1021/acs.jproteome.9b00136. Epub 2019 May 13. J Proteome Res. 2019. PMID: 31055927
-
Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.J Alzheimers Dis. 2021;84(4):1391-1414. doi: 10.3233/JAD-215139. J Alzheimers Dis. 2021. PMID: 34719499 Review.
-
Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics.Mol Neurodegener. 2018 Jan 16;13(1):2. doi: 10.1186/s13024-017-0234-4. Mol Neurodegener. 2018. PMID: 29338754 Free PMC article.
Cited by
-
Amyloid-beta and tau protein beyond Alzheimer's disease.Neural Regen Res. 2024 Jun 1;19(6):1262-1276. doi: 10.4103/1673-5374.386406. Epub 2023 Oct 2. Neural Regen Res. 2024. PMID: 37905874 Free PMC article.
-
Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer's Disease.Aging Dis. 2021 Dec 1;12(8):1964-1976. doi: 10.14336/AD.2021.0719. eCollection 2021 Dec. Aging Dis. 2021. PMID: 34881080 Free PMC article. Review.
-
Key Genes and Biochemical Networks in Various Brain Regions Affected in Alzheimer's Disease.Cells. 2022 Mar 14;11(6):987. doi: 10.3390/cells11060987. Cells. 2022. PMID: 35326437 Free PMC article.
-
Respirasome Proteins Are Regulated by Sex-Hormone Interactions in the Brain.Int J Mol Sci. 2022 Nov 25;23(23):14754. doi: 10.3390/ijms232314754. Int J Mol Sci. 2022. PMID: 36499081 Free PMC article.
-
Pathology and Treatments of Alzheimer's Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes.Molecules. 2024 Dec 16;29(24):5936. doi: 10.3390/molecules29245936. Molecules. 2024. PMID: 39770025 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous